GPT and obesity disorder: ACHE (acetylcholinesterase) [72], FGFR3 [73], VLDLR (very-low-density lipoprotein receptor) [74], SHC1 [75], HDAC6 [76], CHRNA2 [77], CASR (calcium-sensing receptor) [78], ELK1 [79], TYK2 [80], CIITA (class II major histocompatibility complex transactivator) [81], ZAP70 [82], GPT (glutamic-pyruvic transaminase) [83], CHI3L1 [84], AIF1 [85], MMP9 [86], ITGB2 [87], CFD (complement factor D) [88], C3AR1 [89], LGALS1 [90], CD14 [91], TIMP1 [92], TLR2 [93], LTF (lactotransferrin) [94], BRCA2 [95] and IGFBP3 [96] are a potential prognostic markers in obesity.